LU92132I2 - Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium - Google Patents

Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium

Info

Publication number
LU92132I2
LU92132I2 LU92132C LU92132C LU92132I2 LU 92132 I2 LU92132 I2 LU 92132I2 LU 92132 C LU92132 C LU 92132C LU 92132 C LU92132 C LU 92132C LU 92132 I2 LU92132 I2 LU 92132I2
Authority
LU
Luxembourg
Prior art keywords
aclidinium
anion
pharmaceutically acceptable
salt
polyvalent acid
Prior art date
Application number
LU92132C
Other languages
English (en)
French (fr)
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8309225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92132(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of LU92132I2 publication Critical patent/LU92132I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92132C 1999-07-14 2013-01-16 Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium LU92132I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Publications (1)

Publication Number Publication Date
LU92132I2 true LU92132I2 (fr) 2013-03-18

Family

ID=8309225

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92132C LU92132I2 (fr) 1999-07-14 2013-01-16 Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium

Country Status (39)

Country Link
US (16) US6750226B2 (en])
EP (1) EP1200431B3 (en])
JP (2) JP4030040B2 (en])
KR (3) KR100854315B1 (en])
CN (2) CN1272334C (en])
AR (1) AR029760A1 (en])
AT (1) ATE235492T1 (en])
AU (1) AU2005202144B2 (en])
BE (1) BE2013C001I2 (en])
BG (1) BG65565B1 (en])
BR (1) BRPI0012434B8 (en])
CA (1) CA2381165C (en])
CO (1) CO5200759A1 (en])
CY (1) CY2013001I1 (en])
CZ (1) CZ304292B6 (en])
DE (2) DE60001840D1 (en])
DK (1) DK1200431T6 (en])
EE (1) EE04915B3 (en])
EG (1) EG24066A (en])
ES (2) ES2165768B1 (en])
FR (1) FR13C0001I2 (en])
HK (1) HK1042487B (en])
HU (1) HU228594B1 (en])
IL (1) IL147533A0 (en])
LU (1) LU92132I2 (en])
MY (1) MY126959A (en])
NO (2) NO329484B3 (en])
PE (1) PE20010397A1 (en])
PL (1) PL204024B1 (en])
PT (1) PT1200431E (en])
RU (2) RU2264401C3 (en])
SI (1) SI1200431T1 (en])
SK (1) SK287480B6 (en])
TR (1) TR200200768T2 (en])
TW (1) TWI284644B (en])
UA (1) UA73509C2 (en])
UY (2) UY26244A1 (en])
WO (1) WO2001004118A2 (en])
ZA (1) ZA200200232B (en])

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001276497B2 (en) 2000-08-05 2005-04-07 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
PE20020719A1 (es) 2000-12-22 2002-10-11 Almirall Prodesfarma Ag Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
CA2433128C (en) * 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CN101701006B (zh) 2001-09-14 2014-03-05 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
ES2425347T3 (es) * 2001-12-20 2013-10-14 Chiesi Farmaceutici S.P.A. Derivados de carbamato de 1-alquil-1-azoniabiciclo[2.2.2]octano y su uso como antagonistas de receptores muscarínicos
US7405224B2 (en) 2002-01-31 2008-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1590345A1 (en) * 2002-12-23 2005-11-02 Ranbaxy Laboratories, Ltd. Xanthine derivatives as muscarinic receptor antagonists
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
TW200523261A (en) * 2003-07-17 2005-07-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050711A1 (es) * 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
WO2005014005A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
PT1651270E (pt) * 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2005013993A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
ES2358673T3 (es) 2003-10-14 2011-05-12 Glaxo Group Limited Antagonistas de receptores de acetilcolina muscarínicos.
AR046114A1 (es) * 2003-10-17 2005-11-23 Glaxo Group Ltd Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
UY28871A1 (es) * 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
DE602005022499D1 (de) * 2004-05-31 2010-09-02 Almirall Sa Kombinationen mit Antimuskarin-Wirkstoffen und PDE4-Hemmern
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20080319002A1 (en) * 2004-06-16 2008-12-25 Ranbaxy Laboratories Limited Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
EP1879620A2 (en) 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
WO2007016650A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP2281813A1 (en) * 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
EP1978955A1 (en) * 2006-01-06 2008-10-15 Boehringer Ingelheim International GmbH New pharmaceutical compositions based on anticholinergics and andolast
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0710240A2 (pt) 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP2043717A1 (en) * 2006-07-14 2009-04-08 Astra Zeneca AB Inhalation system and delivery device for the administration of a drug in the form of dry powder
WO2008010765A1 (en) 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0622827D0 (en) 2006-11-15 2006-12-27 Glaxo Group Ltd Sheet driver for use in a drug dispenser
WO2008076269A2 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
HRP20110556T1 (hr) * 2007-02-21 2011-09-30 Almirall Novi postupci
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
DK2197841T3 (da) * 2007-09-07 2012-02-06 Theravance Inc Guanidinholdige forbindelser anvendelige som muscariniske receptorantagonister
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
WO2009079392A1 (en) 2007-12-14 2009-06-25 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8329729B2 (en) 2008-05-13 2012-12-11 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
BRPI0912267A2 (pt) 2008-05-23 2015-10-13 Amira Pharmaceuticals Inc sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
MX2010012492A (es) 2008-05-27 2010-12-21 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107955A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120004282A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp, RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CA2758100C (en) 2009-04-09 2017-08-29 Novartis Ag Process for preparing pyrrolidinium salts
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
EP2421835A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
SMT201700481T1 (it) 2009-04-30 2017-11-15 Glaxo Group Ltd Indazoli sostituiti con ossazolo come inibitori di chinasi pi3
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
GB0910537D0 (en) 2009-06-18 2009-07-29 Ivax Pharmaceuticals Ireland Inhaler
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US8735390B2 (en) 2010-09-08 2014-05-27 Glaxosmithkline Intellectual Property Development Limited Polymorphs and salts
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2630126B1 (en) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
AR093795A1 (es) * 2012-12-05 2015-06-24 Chiesi Farm Spa Oxidos de piridinio, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades respiratorias
HRP20221034T1 (hr) 2012-12-17 2022-11-11 Almirall S.A. Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
MY178819A (en) 2013-03-15 2020-10-20 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
AU2014292722B2 (en) * 2013-07-13 2017-03-09 Beijing Showby Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
KR20160058889A (ko) 2013-09-22 2016-05-25 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
CN105658218A (zh) 2013-10-17 2016-06-08 葛兰素史克知识产权开发有限公司 用于治疗呼吸疾病的pi3k抑制剂
US20160263109A1 (en) 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN103755698A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一锅法制备阿地溴铵的工艺
CN103755699A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一种2-羟基-2,2-二噻吩-2-基乙酸-1-氮杂二环[2,2,2]辛-3(r)-基酯制备方法
CZ2014188A3 (cs) 2014-03-26 2015-10-07 Zentiva, K.S. Nové formy aclidinium chloridu a způsob jejich přípravy
EP3122730B1 (en) 2014-03-28 2020-03-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
CA2945069A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CR20160529A (es) 2014-05-12 2017-01-02 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas para tratar enfermedades infecciosas
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
US10155755B2 (en) 2015-03-02 2018-12-18 Ltt Bio-Pharma Co., Ltd. Quinuclidine derivative
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
WO2016162878A1 (en) * 2015-04-04 2016-10-13 Harman Finochem Limited An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i
CZ2015257A3 (cs) 2015-04-16 2016-10-26 Zentiva, K.S. Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu
CN105085355B (zh) * 2015-06-25 2017-11-14 御盛隆堂药业有限责任公司 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
US20190307975A1 (en) 2016-11-21 2019-10-10 Lupin Inc. Medicament dispenser
GB201700727D0 (en) 2017-01-16 2017-03-01 Teva Pharma Inhalers and airflow adaptors therefor
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190076607A1 (en) 2017-09-13 2019-03-14 Lupin Atlantis Holdings Sa Inhaler and mesh for an inhaler
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
WO2019129801A1 (en) 2017-12-28 2019-07-04 Linnea S.A. Process for the purification of methyl-2,2-dithienylglycolate
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
KR20220019015A (ko) 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
PH12022550468A1 (en) 2019-08-28 2023-03-06 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
IL296794A (en) 2020-03-25 2022-11-01 Lupin Inc Multi-carrier medicament dispensers
US20240066037A1 (en) 2020-03-26 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CA3186551A1 (en) 2020-07-23 2022-01-27 Lupin Inc. Dose counter assemblies for medicament dispensers

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8718345D0 (en) * 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132735T2 (de) 1990-09-06 2002-05-29 Pfizer Inc., New York Anti-muscarin bronchodilatoren
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
DE69129188T2 (de) 1990-09-26 1998-07-30 Pharmachemie B.V., Haarlem Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5263480A (en) 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
RU2126248C1 (ru) 1992-12-09 1999-02-20 Берингер Ингельхейм Фармасьютикалз, Инк. Жидкая фармацевтическая композиция в форме аэрозоля
UA27961C2 (uk) 1992-12-18 2000-10-16 Шерінг Корпорейшн Інгалятор для порошкових ліків
HUT76289A (en) 1994-02-10 1997-07-28 Yamanouchi Pharma Co Ltd Carbamate derivative and medicinal composition containing the same
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) * 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
ES2142489T3 (es) 1994-07-29 2000-04-16 Minnesota Mining & Mfg Resina liquida acrilica curable a un material viscoelastomero reticulado.
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CN1142798C (zh) 1995-04-14 2004-03-24 葛兰素惠尔康公司 沙美特罗的计定剂量吸入器
DK0837710T3 (da) 1995-06-21 2002-04-02 Sofotec Gmbh & Co Kg Lægemiddelpulverpatron med integreret doseringsindretning og inhalator for lægemidler på pulverform
AU6392496A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
WO1999065464A1 (en) 1998-06-18 1999-12-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
PT1102579E (pt) 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
EA005028B1 (ru) 2000-01-31 2004-10-28 Пфайзер Продактс Инк. Пиримидинкарбоксамиды, используемые в качестве ингибиторов изозимов pde4
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US6777132B2 (en) 2000-04-27 2004-08-17 Valence Technology, Inc. Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US20020122773A1 (en) 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
JP2004512359A (ja) 2000-10-31 2004-04-22 ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
PE20020719A1 (es) 2000-12-22 2002-10-11 Almirall Prodesfarma Ag Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
CA2433128C (en) 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
PL367085A1 (en) 2001-05-25 2005-02-21 Pfizer Inc. A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
JP2004530705A (ja) 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのｐｄｅ４インヒビター及びチオトロピウム又はその誘導体の組み合わせ
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
CA2459493C (en) 2001-09-14 2011-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions for inhalation
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
ME00077B (me) 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA04011383A (es) 2002-05-17 2005-02-14 Novartis Ag Composicion farmaceutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diuretico.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
PL375631A1 (en) 2002-11-27 2005-12-12 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
MXPA05010160A (es) 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
US20060189642A1 (en) 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
WO2005014005A1 (en) 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
WO2005013993A1 (en) 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
PT1651270E (pt) 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
JP2007500676A (ja) 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
US20050025718A1 (en) 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2551780C (en) 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
DK1713471T3 (da) 2004-02-06 2012-05-14 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme
ES2309705T3 (es) 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
US7712077B2 (en) * 2004-02-27 2010-05-04 International Business Machines Corporation Method and system for instantiating components conforming to the “COM” specification in custom contexts
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DE602005022499D1 (de) 2004-05-31 2010-09-02 Almirall Sa Kombinationen mit Antimuskarin-Wirkstoffen und PDE4-Hemmern
EP1879620A2 (en) 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
JP2010519195A (ja) 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
HRP20110556T1 (hr) 2007-02-21 2011-09-30 Almirall Novi postupci
EP2165159B1 (en) 2007-07-03 2013-07-17 Nxp B.V. Calibration of an amr sensor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
HRP20221034T1 (hr) 2012-12-17 2022-11-11 Almirall S.A. Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća

Also Published As

Publication number Publication date
US9687478B2 (en) 2017-06-27
NO329484B1 (no) 2010-10-25
CZ2002121A3 (cs) 2002-11-13
IL147533A0 (en) 2002-08-14
DK1200431T6 (en) 2015-09-28
US10588895B2 (en) 2020-03-17
CN1272334C (zh) 2006-08-30
CN1373760A (zh) 2002-10-09
ES2193098T7 (es) 2012-12-13
US20080221155A1 (en) 2008-09-11
DK1200431T5 (da) 2005-01-31
US7078412B2 (en) 2006-07-18
US7109210B2 (en) 2006-09-19
BRPI0012434B1 (pt) 2016-03-22
AU2005202144A1 (en) 2005-06-09
MY126959A (en) 2006-11-30
ATE235492T1 (de) 2003-04-15
RU2264401C2 (ru) 2005-11-20
CN100451018C (zh) 2009-01-14
US9333195B2 (en) 2016-05-10
RU2005121162A (ru) 2007-01-20
KR20020021155A (ko) 2002-03-18
US8802699B2 (en) 2014-08-12
US20120122826A1 (en) 2012-05-17
AU2005202144B2 (en) 2007-06-14
CO5200759A1 (es) 2002-09-27
FR13C0001I2 (fr) 2013-11-01
CA2381165F (en) 2001-01-18
AU6433000A (en) 2001-01-30
NO2013002I2 (no) 2013-09-09
CY2013001I2 (el) 2015-10-07
US20160296503A1 (en) 2016-10-13
BRPI0012434B8 (pt) 2021-05-25
ES2165768A1 (es) 2002-03-16
US9056100B2 (en) 2015-06-16
WO2001004118A3 (en) 2001-07-19
FR13C0001I1 (en]) 2013-01-03
UY33494A (es) 2013-04-05
CZ304292B6 (cs) 2014-02-19
KR100854321B1 (ko) 2008-08-26
US7750023B2 (en) 2010-07-06
RU2264401C3 (ru) 2018-06-01
ES2193098T3 (es) 2003-11-01
KR100773844B1 (ko) 2007-11-06
CN1824664A (zh) 2006-08-30
DE60001840T2 (de) 2003-12-11
US20130310353A1 (en) 2013-11-21
NO20020180D0 (no) 2002-01-14
US20050209272A1 (en) 2005-09-22
HUP0202100A3 (en) 2003-09-29
DE60001840D1 (de) 2003-04-30
JP4030040B2 (ja) 2008-01-09
DK1200431T3 (da) 2003-07-21
KR20070007396A (ko) 2007-01-15
HUP0202100A2 (en) 2002-10-28
CA2381165C (en) 2009-10-27
EG24066A (en) 2008-05-08
US20060106056A1 (en) 2006-05-18
US20070099953A1 (en) 2007-05-03
US20140303126A1 (en) 2014-10-09
NO2013002I1 (no) 2013-02-11
US7897617B2 (en) 2011-03-01
KR20070009744A (ko) 2007-01-18
AR029760A1 (es) 2003-07-16
ES2165768B1 (es) 2003-04-01
JP4951217B2 (ja) 2012-06-13
US6750226B2 (en) 2004-06-15
RU2306312C2 (ru) 2007-09-20
TWI284644B (en) 2007-08-01
EE200200017A (et) 2003-04-15
NO329484B3 (no) 2013-04-29
DE60001840T3 (de) 2015-10-08
US20030055080A1 (en) 2003-03-20
JP2005350476A (ja) 2005-12-22
UY26244A1 (es) 2000-12-29
US8513279B2 (en) 2013-08-20
EP1200431A2 (en) 2002-05-02
UA73509C2 (uk) 2005-08-15
AU779881B2 (en) 2005-02-17
US20100234333A1 (en) 2010-09-16
PE20010397A1 (es) 2001-04-11
KR100854315B1 (ko) 2008-08-26
CY2013001I1 (el) 2015-10-07
US8129405B2 (en) 2012-03-06
US7196098B2 (en) 2007-03-27
BE2013C001I2 (en]) 2019-05-21
SK287480B6 (sk) 2010-11-08
US20110118223A1 (en) 2011-05-19
WO2001004118A2 (en) 2001-01-18
SI1200431T1 (en) 2003-10-31
BG65565B1 (bg) 2008-12-30
ZA200200232B (en) 2003-04-10
EE04915B3 (et) 2016-07-15
US10034867B2 (en) 2018-07-31
US20040132768A1 (en) 2004-07-08
NO20020180L (no) 2002-03-13
SK432002A3 (en) 2003-04-01
BG106301A (en) 2002-08-30
US7358260B2 (en) 2008-04-15
EP1200431B1 (en) 2003-03-26
HK1042487B (en) 2003-07-18
PL204024B1 (pl) 2009-12-31
HU228594B1 (en) 2013-04-29
TR200200768T2 (tr) 2002-07-22
DE60001840T4 (de) 2015-11-26
EE04915B1 (et) 2007-10-15
US20170319557A1 (en) 2017-11-09
USRE46417E1 (en) 2017-05-30
CA2381165A1 (en) 2001-01-18
BR0012434A (pt) 2002-04-02
PL357160A1 (en) 2004-07-12
US20150246026A1 (en) 2015-09-03
US20190183867A1 (en) 2019-06-20
EP1200431B3 (en) 2015-06-24
JP2003504368A (ja) 2003-02-04
PT1200431E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
LU92132I2 (fr) Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium
UA89181C2 (ru) Комбинация, которая содержит антимускариновые агенты и кортикостероиды
BG106158A (en) New use of compounds as antibacterial agents
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
DK0574313T3 (da) 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
MY130441A (en) Solutions containing epinastin
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
MY125414A (en) Aminopropylphosphinic acids
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
HUP0000728A2 (hu) Naftiridinkarbonsavszármazék sója, eljárás előállítására és a vegyületet tartalmazó gyógyászati készítmény
AU8111798A (en) Resolution of amines
EE04491B1 (et) (+)-nortsisapriidi kasutamine
SE0102055D0 (sv) New Compounds
GR850309B (en])
SE0102440D0 (sv) New compound
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
YU46914B (sh) Metoksimetilna jedinjenja
MY133438A (en) Morpholinobenzamide salts
FI930462A0 (fi) Aminobensoesyraderivat
TR199901631T2 (xx) Klavülanik asitin esterleri ve tuzlarının hazırlanması için işlem.